OBJECTIVE: To examine a 2-year cohort of patients treated with brachytherapy to determine the likelihood of unfavorable pathologic features using a nomogram recently developed at our center to estimate the likelihood of Gleason score upgrading for patients with favorable prostate cancer undergoing radical prostatectomy. The brachytherapy outcomes for patients with a high likelihood of upgrading were compared with those with a lower likelihood to affirm the effectiveness of brachytherapy in this setting. Information on the likelihood of upgrading could help in the selection between active treatment and surveillance for patients with favorable-risk prostate cancer. METHODS: The records were examined for 259 men undergoing prostate brachytherapy in 2006 to 2007, of whom 217 had favorable risk cancer. The likelihood of Gleason score upgrading (GSU) was predicted using the radical prostatectomy-derived nomogram. RESULTS: The median age was 62 years (range 44-77), and the median prostate-specific antigen level was 4.71 ng/mL (range 0.56-9.87). Central pathology review was available for 88%, and 83% had undergone extended biopsies. Two men had received androgen deprivation therapy for prostate downsizing. The median predicted likelihood of GSU was 51.2%. The median prostate-specific antigen level for 199 patients without treatment failure after a median follow-up of 4.2 years in this cohort was 0.07 ng/mL (interquartile range undetectable to 0.23). CONCLUSION: In the present cohort of patients with favorable-risk prostate cancer treated with brachytherapy, the estimated likelihood of GSU using the surgically derived nomogram was substantial. Follow-up with prostate-specific antigen measurement has indicated that brachytherapy is a highly effective treatment option despite less favorable clinical and pathologic factors. Patients should not be discouraged from brachytherapy on the basis of a high likelihood of GSU.
OBJECTIVE: To examine a 2-year cohort of patients treated with brachytherapy to determine the likelihood of unfavorable pathologic features using a nomogram recently developed at our center to estimate the likelihood of Gleason score upgrading for patients with favorable prostate cancer undergoing radical prostatectomy. The brachytherapy outcomes for patients with a high likelihood of upgrading were compared with those with a lower likelihood to affirm the effectiveness of brachytherapy in this setting. Information on the likelihood of upgrading could help in the selection between active treatment and surveillance for patients with favorable-risk prostate cancer. METHODS: The records were examined for 259 men undergoing prostate brachytherapy in 2006 to 2007, of whom 217 had favorable risk cancer. The likelihood of Gleason score upgrading (GSU) was predicted using the radical prostatectomy-derived nomogram. RESULTS: The median age was 62 years (range 44-77), and the median prostate-specific antigen level was 4.71 ng/mL (range 0.56-9.87). Central pathology review was available for 88%, and 83% had undergone extended biopsies. Two men had received androgen deprivation therapy for prostate downsizing. The median predicted likelihood of GSU was 51.2%. The median prostate-specific antigen level for 199 patients without treatment failure after a median follow-up of 4.2 years in this cohort was 0.07 ng/mL (interquartile range undetectable to 0.23). CONCLUSION: In the present cohort of patients with favorable-risk prostate cancer treated with brachytherapy, the estimated likelihood of GSU using the surgically derived nomogram was substantial. Follow-up with prostate-specific antigen measurement has indicated that brachytherapy is a highly effective treatment option despite less favorable clinical and pathologic factors. Patients should not be discouraged from brachytherapy on the basis of a high likelihood of GSU.
Authors: John G Phillips; Ayal A Aizer; Ming-Hui Chen; Danjie Zhang; Michelle S Hirsch; Jerome P Richie; Clare M Tempany; Stephen Williams; John V Hegde; Marian J Loffredo; Anthony V D'Amico Journal: Clin Genitourin Cancer Date: 2014-03-03 Impact factor: 2.872
Authors: Carlos Antônio da Silva Franca; Sérgio Lannes Vieira; Antonio Carlos Pires Carvalho; Antonio Jose Serrano Bernabe; Antonio Belmiro Rodrigues Campbell Penna Journal: Radiol Bras Date: 2014 Mar-Apr
Authors: Andrew Warner; Tom Pickles; Juanita Crook; Andre-Guy Martin; Luis Souhami; Charles Catton; Himu Lukka; George Rodrigues Journal: Cureus Date: 2015-06-11
Authors: Sue M Evans; Varuni Patabendi Bandarage; Caroline Kronborg; Arul Earnest; Jeremy Millar; David Clouston Journal: Prostate Int Date: 2016-08-03